Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: microRNA therapeutics - Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - Regulus Therapeutics

Alternative Names: anti-miR-10b; anti-miR-122; miR-296; miR-34; miR-34a; miR-K12-11 (viral oncomir); miR-X; miRNA therapeutics - Regulus Therapeutics; RGLS 5579; Viral microRNAs - Regulus Therapeutics

Latest Information Update: 11 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator California Institute of Technology/CalTech; Stanford University
  • Developer Cenix BioScience; Regulus Therapeutics
  • Class Antihyperglycaemics; Antisense oligonucleotides; Antivirals; Cardiovascular therapies; Hepatoprotectants; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Hepatitis B; Hepatitis C; Non-alcoholic steatohepatitis
  • Discontinued Diabetes mellitus; Heart failure; Metabolic syndrome; Viral infections

Most Recent Events

  • 08 Jan 2019 Pharmacodynamics data from preclinical studies in Glioblastoma released by Regulus Therapeutics
  • 20 Nov 2018 Updated pharmacodynamic data from preclinical study in Glioblastoma released by Regulus Therapeutics
  • 26 Sep 2018 Pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis, Glioblastoma and Hepatitis B released by Regulus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top